论文部分内容阅读
目的探讨肾移植术后恶性肿瘤的发生与人类白细胞抗原(HLA)抗原频率的关系。方法对具有HLA分型的肾移植术后发生恶性肿瘤的107例患者进行HLA抗原频率分析。107例肾移植术后肿瘤患者分为4组,肾盂输尿管癌组,42例;膀胱肿瘤组,19例;其他泌尿系肿瘤组,14例;其他非泌尿系肿瘤组,32例。肾移植术后未发生恶性肿瘤的肾移植患者作为正常对照组,共计1 131例。结果在107例肾移植术后发生恶性肿瘤患者中,泌尿系统肿瘤75例,占肾移植术后发生恶性肿瘤患者的70.09%(75/107)。肾盂输尿管恶性肿瘤组HLA-A30、其他泌尿恶性肿瘤组的HLA-A32抗原频率与肾移植术后未发生恶性肿瘤的肾移植患者比较,差异有统计学意义(P均<0.05)。其他泌尿系肿瘤组中HLA-B62与肾移植术后未发生恶性肿瘤的肾移植患者比较,差异有统计学意义(P<0.05)。在HLA-DR抗原频率中,未发现与HLA相关的HLA-DR抗原,HLA-DR1在膀胱癌和其他泌尿癌中均未出现,HLA-DR17、DR10在肾盂癌和其他泌尿系癌中均未出现。在HLA-DQ抗原频率中,膀胱癌组HLA-DQ9的抗原频率与未发生恶性肿瘤的肾移植患者比较,差异有统计学意义(P<0.05)。结论某些HLA抗原与肾移植术后患者发生恶性肿瘤具有一定的关联。
Objective To investigate the relationship between the occurrence of malignant tumors and the frequency of human leukocyte antigen (HLA) antigen after renal transplantation. Methods The frequency of HLA antigens in 107 patients with malignant tumors after renal transplantation with HLA typing was analyzed. One hundred and seven patients with renal transplantation were divided into 4 groups: 42 cases in ureteropelvic cancer group, 19 cases in bladder tumor group, 14 cases in other urological tumor group and 32 cases in other non-urological tumor group. Kidney transplant patients without malignant tumors as a normal control group, a total of 1 131 cases. Results Of the 107 patients who developed malignant neoplasms after kidney transplantation, 75 cases of urological tumors accounted for 70.09% (75/107) of those with malignant tumors after renal transplantation. The frequency of HLA-A30 in patients with ureteropelvic malignancies was significantly higher than that in patients without renal neoplasms (P <0.05). In other urological tumor groups, there was significant difference between HLA-B62 and renal transplant recipients without renal cancer (P <0.05). HLA-DR antigen was not found in the HLA-DR antigen frequency, HLA-DR1 was not found in bladder cancer and other urinary cancers, and HLA-DR17 and DR10 were not found in renal pelvis and other urological cancers appear. In the frequency of HLA-DQ antigen, the frequency of HLA-DQ9 antigen in bladder cancer group was significantly higher than that in non-malignant kidney transplantation group (P <0.05). Conclusion Some HLA antigens are associated with malignant tumors in patients after kidney transplantation.